Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other Non-Current Liabilities (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Other Non-Current Liabilities data on record, last reported at $3.6 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 17.45% year-over-year to $3.6 million; the TTM value through Sep 2025 reached $3.6 million, down 17.45%, while the annual FY2024 figure was $6.6 million, 248.19% up from the prior year.
  • Other Non-Current Liabilities reached $3.6 million in Q3 2025 per BTAI's latest filing, up from $2.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $21.2 million in Q1 2024 and bottomed at $1.9 million in Q3 2022.
  • Average Other Non-Current Liabilities over 4 years is $4.7 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: soared 724.48% in 2024, then tumbled 84.57% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $2.3 million in 2022, then dropped by 18.69% to $1.9 million in 2023, then surged by 248.19% to $6.6 million in 2024, then tumbled by 45.65% to $3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $3.6 million in Q3 2025, $2.6 million in Q2 2025, and $3.3 million in Q1 2025.